



# ALPHABETICAL INDEX OF EXHIBITORS

1.	A4Cell	
2.	AbilityPhama	
3.	Acellera Therapeutics	
4.	Almirall	
5.	Anaxomics Biotech	
6.	APICES - CRO	
7.	BCN Peptides	
8.	BeCytes Biotechnolgies	18
9.	Biomar Microbial Technologies	
10.	CancerAppy	
11.	Cebiotex	
12.	Certest Pharma	
13	Cocoon Bioscience	



14.	CONNECTA Therapeutics	24
15.	Curapath	25
16.	CZ Vaccines	26
17.	DeepLabs	27
18.	Diversa	28
19.	GP Pharm	29
20.	Grifols Engineering	30
21.	i+Med	31
22.	Invesbiofarm	32
23.	Kymos Group	33
24.	Laboratorios Farmacéuticos ROVI	34
25.	Laminar Pharmaceuticals	35
26.	Life Length Laboratories	36
27.	Mikrobiomik Healthcare	37
28.	Oniria Therapeutics	38
29.	Protein Alternatives	39
30.	Remab Therapeutics	40
31.	Specipig	41
32.	Unikare Bioscience	42




#### Companies & sectors






#### Companies & sectors





#### Pharmaceutical Development

#### Diagnostic









# EXHIBITING COMPANIES BOOTH 2024

# A4Cell

Elena Rivas Pérez **CEO** 

info@a4cell.com (+34) 910 679 519

www. a4cell.com

in  $X \square$ 

A4Cell leads scientific innovation with its pioneering cell assays, transforming research through live single-cell imaging.

Their lab-in-a-cell approach, powered by SPAchip® technology, enables real-time monitoring of cellular dynamics. SPAchip® devices, integrating silicon oxide microparticles and fluorescent probes, allow detection of biomolecules over days in a single cell culture, capturing dynamic changes.

This breakthrough offers unprecedented insight into cellular activities, enhancing precision and reliability in research. A4Cell's solutions facilitate in-depth exploration of disease mechanisms, advancing our understanding of biology and driving progress in life sciences.

#### **Trademarks:**

SPAchip®









### Ability Pharmaceuticals

Carles Domènech
Executive Chairman and CEO

contact@abilitypharma.com

www. abilitypharma.com

f in X 🗅

AbilityPharma is a biopharmaceutical company developing first-in-class compounds in cancer focused on autophagy as an innovative approach to selectively kill cancer cells.

ABTL0812 has completed the recruitment in a phase 2b double-blind placebo-controlled clinical trial in 140 patients with metastatic pancreatic cancer in USA, Spain, France and Israel, with a positive interim analysis in April 2024. Results are expected in Q4 2024.

The product also completed with positive results an international phase 2a trial in endometrial cancer and lung cancer.

#### **Trademarks:**

AbilityPhama

## Acellera Therapeutics

Franck Chevalier
Head of Business Development

info@acellera.com

www. acellera.com

in X

Acellera Therapeutics' mission is to leverage cutting-edge computational techniques to accelerate the discovery of novel therapeutics for unmet medical needs. Our proprietary technology simulates interactions between proteins and small molecules with atomic precision to obtain new hypotheses, generate relevant big data and predict accurately molecule properties. Al is used to extract information over large, high-dimensional datasets and to direct machine learninginformed physics models. Our business model includes scientific and technological partnerships in drug discovery. Early drug discovery services and software licensing are available as well. Our approach is backed by the scientific community (57 peer reviewed articles) and demonstrated by numerous successful collaborations.

#### **Trademarks:**


ACEMD™, PlayMolecule™, Acellera™



12







# Almirall

Josep-Maria Casanovas, Ph.D. Vice President, External Innovation & Licensing

josep-maria.casanovas@almirall.com

www. almirall.com

f & in D

We are a global pharmaceutical company dedicated to medical dermatology. As a family-owned business, we think in generations and apply this long-term view to our contributions to people with skin conditions, dermatology, and society. Our passion for medical dermatology and our collaborative mindset enable us to develop and deliver innovative and impactful treatments for people with skin diseases to transform our patients' world by helping them to realize their hopes and dreams for a healthy life.

### Anaxomics Biotech

Mireia Coma
Business Development Director
& Medical Director

mcoma@anaxomics.com (+34) 648 789 862

www. anaxomics.com

in  $X \square$ 

Anaxomics is an Al biotech company that uses cutting-edge technologies based on Systems Biology and Machine Learning to overcome challenges in drug discovery and development process. We are specialized in In Silico Clinical Trials, which lets our clients anticipate the outcomes, potential challenges, and risks of forthcoming clinical trials, as well as gaining a molecular-level understanding of completed clinical trials.







### BCN peptides



### APICES - CRO

Samir Barral El Gaoui Business Development Manager

samir.barral@apices.es (+34) 648 705 512

www. apices.es

in X 🖸

APICES is a European CRO providing Global Clinical Research services, with more than 15 years of experience conducting clinical trials and RWE studies and ensuring that clients are delighted with its work. APICES offers to customers clinical research services to improve the quality of investigational products development optimizing the processes and activities of clinical research. For us, success in clinical trials means:

- Fast Recruitment Focus
- Adaptability and Flexibility
- Local Expertise and European Reach
- Stable and Experienced Staff
- > 100 acknowledgements in publications
- KNOW HOW AND KNOW WHO

# BCN Peptides

Helena Sabata Perez Business Development Manager

hsabata@bcnpeptides.com

www. bcnpeptides.com

in

BCN Peptides is a privately owned CDMO based in Barcelona, completely focused on the GMP manufacturing of Bioactive Peptides for pharmaceutical, veterinary, and cosmetic applications.

We are a customer-oriented company targeting to fulfil the client's needs at each stage of peptide drug development, while consistently upholding the highest quality standards.

With a deep expertise in GMP peptide production, BCN Peptides is recognized as a leader in the field, providing reliable and high-quality peptide manufacturing services to global partners.











# BeCytes Biotechnologies

### Estephan Arredondo Technical Director

earredondo@cytesbiotech.com Info@cytesbiotech.com (+34) 93 403 45 53

www. becytes.com

in X

BeCytes Biotechnologies is a biotechnological company that offers products and services based on tissue procurement, cell isolation, and cell solutions for in vitro models addressed to the research community worldwide. Our main area of expertise is the production of primary liver cells from human and animal origin.

Furthermore, BeCytes Biotechnologies has created a platform capable of coordinating the donation of human tissues and cells for biomedical research purposes, which encompasses strong collaborations with national and international procurement centers.

#### **Trademarks:**

BeCytes Biotechnologies

# Biomar Microbial Technologies

Miguel Fernández Medarde Business Development Manager

m.fernandez@biomarmt.com (+34) 987 849 200

www. biomarmt.com

f 3 in

Biomar offers access to a collection of 75.000 strains and the compounds they produce to clients in different industrial areas.

Biomar has also a fermentation plant with volumes up to 3.000 L to produce the candidates and optimize the process.

The company has also internal developments of different agriculture products like fungicides, nematicides or biostimulants.









# CancerAppy

Luis Martin

I.martin@cancerappy.com

www. cancerappy.com

in D

We are developing a strong and continuously growing pipeline of new cancer therapies with our Al platform.

Our 3 most advanced programs are:

CA04 First-in-class antibody, High specificity of the antibody in the preclinical phase in vitro.

In vivo data: after 21 days of treatment, in which the control has tripled the size of the initial tumor, and those treated with the ADC have completely remitted.

CA08 Best-in-class Kinase inhibitor.

In vitro tests with positive results. Improves the results of commercial inhibitors in cell proliferation assays.

### Cebiotex

Joan Bertran Llavina
CEO & Founder

info@cebiotex.com

www. cebiotex.com

in

Cebiotex is an innovative clinical stage start-up, spin-off of the Sant Joan de Déu Hospital (HSJD) and the Universitat Politècnica de Catalunya (UPC) all based in Barcelona (Spain).

Cebiotex current mission is to transform the future of surgical oncology for better outcomes to improve cancer patients, adult and paediatric, through its unique CEBIOTEX® Technological Platform, patented in US, EU, China and Japan, and with broad therapeutic applications, First drug in advanced clinical development, CEB-01, is an innovative pharmaceutical product for local control of Soft Tissue Sarcomas (STS) after tumour removal. Clinicaltrials.gov NCT04619056. Future perspective is to provide solutions in other cancer indications and therapeutic applications.

An exploratory trial for Pancreatic Cancer and a Pediatric Investigation Plan have also been submitted.

#### **Trademarks:**

Cebiotex®




20

Cepiotexe





# Cocoon



# Certest Pharma

Jesús Aznar Business Development Manager Pharma

jaznar@certest.es (+34) 617 944 081

www. pharma.certest.es

in

Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Our licensable technology includes top-performing proprietary ionizable lipids (our main asset) and optimized LNP formulations with excellent performance in vivo and which can induce extrahepatic delivery.

We also offer design, production, and analysis of oligonucleotides in GMP-like quality.

Certest Pharma provides cutting-edge solutions with different payloads for RNA therapies and collaborate with various partners to enhance global healthcare.

### Cocoon Bioscience

Joshua Robinson

jrobinson@cocoonbio.com (+1) 812 760 6428

www. cocoonbio.com

in

Cocoon Bioscience manufactures specialty enzymes and proteins for the life science and pharmaceutical industries. Manufacturing is done using a novel platform that takes advantage of insects in their chrysalis state as natural bioreactors, producing high performance, affordable enzymes with rapid scaling from milligram to kilogram quantities.











# CONNECTA Therapeutics

Jordi Fàbrega Casadellà Co-Founder & CEO

www. connectatherapeutics.com

in X

CONNECTA Therapeutics is a clinical stage biotech company developing new treatments for CNS diseases with a strong commitment to orphan and paediatric indications.

CONNECTA's leading program CTH120, in clinical development, is a first-in-class neuroplasticity modulator with a clinically validated safety profile and broad therapeutic application.

CONNECTA plans to start CTH120's Phase II clinical trial in Fragile X Syndrome in the first half of 2025.

CONNECTA is looking for licensing out or co-development opportunities and investors for its next funding round.

#### **Trademarks:**

CONNECTA Therapeutics®

# Curapath

Amador Garcia

Business Development Director

agarcia@curapath.com (+34) 667 928 070

www. curapath.com

in

Curapath specializes in the design, development, and cGMP manufacturing of cutting-edge polymer and lipid-based drug delivery systems, including polymer nanoparticles (PNPs) and lipid nanoparticles (LNPs). Equipped with state-of-the-art facilities, Curapath offers GMP manufacturing capabilities for polymer and lipid-based therapeutics, ensuring seamless scale-up, meticulous analytical development, and a comprehensive CMC package.



### **:CZ**V/CCINES

# /deeplabs



### CZ Vaccines

Mercedes Rodríguez Commercial Director CDMO Human Biologicals

Mercedes.rodriguez@czvaccines.com (+34) 630 456 502

www.

czvaccines.com

in



CZ Vaccines is an ideal partner for any organization intending to advance their biologic product candidates from development scale to clinical Phase I to III, and commercial supplies capability. Your partner for BIOLOGICS manufacturing

- Live & Inactivated Bacteria & Viral Vaccines up to BSL-2
- Sterile processing systems
- Process Development / Optimisation (Upstream / Downstream)
- Scale-up and cGMP manufacturing
- Aseptic filling into vials
- Lyophilization (clinical trial material and large scale)
- Quality control testing: Microbiological: Sterility-non-sterility, Chemical-Physical and Biological
- Labeling & packaging
- DS & DP release
- Storage: (+2-8°C), (-20°C), (-80°C)

# DeepLabs

Pilar Gil CEO

pg@deeplabs.es

www. deeplabs.es

in

DeepLabs manages Life Science districts in Madrid and Barcelona offering laboratory and office buildings creating ecosystems for innovative companies focused on Life Science and Technology.


MASID, Madrid Science and Innovation District, and BASID, Barcelona Science and Innovation District are districts with more than 60.000 sqm and 3.000 professionals each, and with available spaces to grow.

In both districts we offer flexible space with private laboratories and offices, access to shared core facilities, meeting rooms, restaurants and other general facilities.



# **D**||VERSA







### Guillermo Calvo Navarrete Business Developer

guillermo.calvo@diversatechnologies.com

www. diversatechnologies.com

in X

At Diversa, we specialize in advanced drug delivery solutions using patented lipid nanoparticles. We focus on improving bioavailability and targeting of therapeutics, especially for poorly soluble drugs, nucleic acid therapies, and protein-based treatments.

Our platform benefits pharmaceutical, biotech, dermocosmetic, and nutraceutical companies. We seek partnerships with entities in drug development and therapeutic innovation to address delivery challenges, particularly enhancing bioavailability, targeted delivery, solubility, and safety profiles.

### GP Pharm

Santi Marfà BD Manager

smarfa@gp-pharm.com

www. gp-pharm.com

in

GP Pharm is a privately owned pharmaceutical company based in Barcelona (Spain). GP Pharm is specialized in the development, manufacture, and marketing of complex generic injectable products. Our products are based on our in-home developed drug delivery systems using technological platforms based on Microspheres and Liposomes and/or peptides API's.

GP Pharm portfolio is developed towards the fields of Urology, Oncology and Women Health therapeutic areas.

The activities of the company are essentially focused in out-licensing of our portfolio and CDMO activities.

#### Trademarks:

Lutrate, Nictur, Duratil, Astarté.





28

# GRIFOLS WE ENGINEERING KNOW HOW





# Grifols Engineering

Oriol Mora

Director, External Projects MGMT

www. grifolsengineering.com

Grifols Engineering is a company specialized in biotech and sterile manufacturing processes. Grifols Engineering offers consultancy and engineering services and also machinery development for the biotech industry (Ultrafiltration, fermentors, CIP's, etc). We offer the design and construction of tailor-made solutions: the precise application or specific machine which cannot be found on the market. We work in two project management models: -Integral "turnkey" project management & -Project management in stages: Conceptual design, Basic and detailed engineering, Implementation, start up.

### i+Med

Miguel Ucelay López de Heredia Business Development

business@imasmed.com (+34) 945 561 134

www. imasmed.com



i+Med is a pharmaceutical company devoted to the research, development and manufacturing of biomedical devices and innovative medicines with high added value.

We are knowledge generators. A cooperative of scientists positioned as one of the world leaders in the field of nanohydrogels and controlled release.

We are specialists in the development of smart nanohydrogels and controlled-release of active ingredients. We apply our expertise around different technologies, supported by our 6 patents, thus customizing different solutions tailored to our client's needs.

#### **Trademarks:**

BtH, TrH, OpH, DayDrop, Profilm, Revodiol, BuddyDrop.





30







### Invesbiofarm

# Gabriella Russo Project Development Manager

projectdevmanager@invesbiofarm.com (+34) 958 637 152

www. invesbiofarm.com inveskin.com





Invesbiofarm is a biotechnology company focused on the development and manufacture of dermatological, cosmetic and and class III injectable hyaluronic acid medical devices.

We have our own R&D laboratory, quality control and microbiology and manufacturing plant for sterile and semisolid products.

We work under GMP ISO 22716. We are also a CDMO company.

Our products, some of which are already on the market, are based on multinationally patented preservation and stabilisation process. The results of our clinical trials show significant efficacy in the treatment of various dermatological conditions, including atopic dermatitis/eczema, woman health, and acne..

#### **Trademarks:**

Inveskin, Wiotech, Invesderm.

# Kymos Group

Cosme Aragonés Corporate Director of Business Development caragones@kymos.com (+34) 615 865 448

www. kymos.com



Kymos is an analytical CRO devoted to bioanalysis and CMC services for small molecules, biologics, and nucleic acids. We are GMP and GLP certified, and we have been inspected by EMA and FDA. We work for biotechnology, pharmaceutical, veterinary, fine chemistry, cosmetics, and nutraceutical industries. HQ and main lab are based in Barcelona with two additional sites in Ancona and Frankfurt.


#### **Trademarks:**

KYMOS, PHARMAPROGRESS, PROLYTIC.









### Laboratorios Farmaceuticos ROVI

Lucía Morillo

Business Development Manager

bd@rovi.es

www.

in

ROVI is a public pan-European company (ticker: ROVI) with a market cap of around 3,8B EUR and revenues of 830 M EUR in 2023. ROVI'S HQ are based in Madrid, Spain and we have direct presence in Germany, France, UK, Italy, Portugal, Poland and Austria.

Risvan® is a new highly efficacious and well-tolerated monthly LAI treatment for unstable Schizophrenia patients with severe and moderate symptoms undergoing a relapse and for the long-term treatment. It's approved by EMA and US FDA.

# Laminar Pharmaceuticals

Victoria Lladó Cañellas USA CSO & Strategy

Victoria.llado@laminarpharma.com

www. laminarpharma.com



Laminar Pharmaceuticals is a pioneering biopharmaceutical company focused on drug discovery, rational design, and clinical development. All our compounds are based on a novel therapeutic approach: Membrane Lipid Therapy (Melitherapy), which focuses on targeting and normalizing membrane lipids. Our objective is to provide a solution to serious diseases with unmet clinical needs, such as glioblastoma, where our most advanced compound, LAM561, is in a pivotal Phase 2/3 clinical trial for approval and potential commercialization.











# Life Length Laboratories

Dr. Enrique Samper
Chief Business and Transformation Officer

esamper@lifelength.com (+34) 674 372 928

www. lifelength.com

f ♂ in X □

Life Length is the world leading diagnostic services company specialized in the quantification of telomeres and telomerase, robust biomarkers of aging and age-related diseases.

We measure individual telomeres in single cells by our patented and CLIA certified Telomere Analysis Technology, using confocal microscopy and proprietary software. We also quantify telomerase activity by our CLIA certified Quantitative-TRAP analysis, and related biomarkers.

## Mikrobiomik Healthcare

Juan Basterra

jbasterra@mikrobiomik.net (+34) 944 540 166

www. mikrobiomik.net

in X ▶

MBK-01 is a biological medicine based on intestinal microbiota with FSPIM® technology. It consists of 4 lyophilized oral capsules and is intended for various indications. The phase III clinical trial for Clostridioides Difficile Infection concluded with patient recruitment completed in November 2023. We are currently preparing to submit the regulatory dossier to the EMA, which has granted MBK-01 designation as a new active substance, enabling commercialization in the EU by 2025 through a centralized procedure.











# Oniria Therapeutics

### Esther Riambau **CEO**

eriambau@oniriatherapeutics.com (+34) 620 006 316

#### www. oniriatherapeutics.com

in X

Oniria Therapeutics is a biopharmaceutical company in the field of precision oncology and focused on cancer persistence.

ONR-001 is a first-in-class molecule that allosterically activates TET2, a master epigenetic enzyme, causing tumor cells to enter cycle arrest and even die.

We have already demonstrated efficacy in Melanoma, Colorectal cancer and Acute Myeloid Leukemia, with high tolerability in rodents.

EpiGold-G is a Companion Diagnostic test that permits identify ONR-001 responders as well as target treatment engagement.

# Protein Alternatives

### Dr. Juan Ignacio Imbaud **CEO**

proalt@proteinalternatives.com (+34) 918 047 322

www. proteinalternatives.com

in  $\mathbb{X}$ 

Therapeutic monoclonal antibodies in oncology: Anti-CDH17 and Anti-IL13Ra2 monoclonals for the treatment of metastatic colorectal cancer (mCRC). Development stage: preclinical.

SEC6 genetic signature for recurrence prediction and treatment guidance of colorectal cancer patients in Stage II. Development stage: ongoing proof of concept/demonstration study.

Minimally invasive biomarker-based test for early detection of lung cancer in blood and/or saliva. Development stage: ongoing prototype validation.

#### **Trademarks:**


PROTEIN ALTERNATIVES, COLODETECT











# Remab Therapeutics

Rafael Mañez
President & CMO

info@remabtx.com

www. remabtx.com

in X

RemAb Therapeutics is a company developing molecules for the intracorporeal removal of harmful antibodies. The company pipeline includes molecules to remove antibodies in allergic and autoimmune diseases, anti-ABO blood group antibodies, antibodies neutralizing adenoviruses used for gene therapy, and antibodies acting as enhancers of infections. We are at the clinical stage for the latter indication, specifically for preventing nosocomial Gram-negative infections, including those resistant to antibiotics.

# Specipig

Assela Bosch
Head of Commercial and BD

assela.bosch@specipig.com (+34) 671 020 270

www. specipig.com


in X

SPECIPIG, is a pioneer Biomedical Preclinical Research Centre (CRO) focused on the pig. We are experts in preclinical studies of medical device, tissue regeneration, stem cells, new materials and pharma products. We develop customized disease models. SPECIPIG is GLP and ISO 13485 certified, has executed projects submitted to the FDA and follows CE regulations regarding animal research, health and welfare.









# Unikare Bioscience

Andrea Zapater Matute
R&D Account Manager

unikare@unikare.eu

www. unikare.eu

**♂** in

Unikare Bioscience develops innovative dermatological and cosmetic products by providing the best solutions based on scientific knowledge.

We work on the basis of polymeric nanogel technology and other nano-vehicles, preserving these substances and facilitating their penetration and increasing their effectiveness.

We believe that effective and transformative skin care is created with cutting-edge science and a radically new approach, based on the most innovative advances in nanoencapsulation and carrier principles. Unikare Bioscience brings these approaches, characteristic of new pharmaceutical developments, to the world of cosmetics and personal care.

#### **Trademarks:**

Sibari Republic, Onak





# **Spain**

Trade Commission of Spain 500 North Michigan Avenue, Suite 1500 Chicago, IL 60611, USA Phone +1 321 644 1154 www.spainbusiness.com

ICEX Spain Trade and Investment Paseo de la Castellana, 278 28046 Madrid, Spain Phone +34 913 491 868 www.icex.es



e-catalogue













